December 9th- ASH 2025 Spotlight: inMMyCAR: First-in-Human In Vivo CAR-T for Relapsed/Refractory Myeloma CME Congresses . December 9th- ASH 2025 Spotlight: inMMyCAR: First-in-Human In Vivo CAR-T for Relapsed/Refractory Myeloma December 9th- ASH 2025 Spotlight: MajesTEC-3: A Landmark Phase 3 Trial in Relapsed/Refractory Myeloma CME Congresses . December 9th- ASH 2025 Spotlight: MajesTEC-3: A Landmark Phase 3 Trial in Relapsed/Refractory Myeloma December 9th- ASH 2025 Spotlight: Real-World Symptom Improvement With Belumosudil in Chronic GVHD CME Congresses . December 9th- ASH 2025 Spotlight: Real-World Symptom Improvement With Belumosudil in Chronic GVHD December 9th- ASH 2025 Spotlight: Response Dynamics to Belumosudil in Chronic GVHD CME Congresses . December 9th- ASH 2025 Spotlight: Response Dynamics to Belumosudil in Chronic GVHD December 8th- ASH 2025 Highlight: MaaT013 in Steroid- and Ruxolitinib-Refractory Acute GI GVHD CME Congresses . December 8th- ASH 2025 Highlight: MaaT013 in Steroid- and Ruxolitinib-Refractory Acute GI GVHD December 8th- ASH 2025 Highlight: What’s New in Myeloid Malignancies at ASH 2025? CME Congresses . December 8th- ASH 2025 Highlight: What’s New in Myeloid Malignancies at ASH 2025? December 7th- ASH 2025 Spotlight: The Rise of Golcadomide CME Congresses . December 7th- ASH 2025 Spotlight: The Rise of Golcadomide December 7th- ASH25 Highlights: What’s New in Lymphoid Malignancies at #ASH25? CME Congresses . December 7th- ASH25 Highlights: What’s New in Lymphoid Malignancies at #ASH25? December 6th- ASH 2025 Spotlight: The VERIFY Trial CME Congresses . December 6th- ASH 2025 Spotlight: The VERIFY Trial December 6th- ASH 2025 Spotlight: The HD21 Trial CME Congresses . December 6th- ASH 2025 Spotlight: The HD21 Trial Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Page21 Page22 Page23 Page24 Page25 Page26 Page27 Page28
